Roche unveils AXELIOS 1 for enhanced next-generation sequencing
The AXELIOS 1 platform offers flexible, high-throughput sequencing suitable for diverse research needs, from small studies to large genomic projects, aiming to accelerate discoveries in disease understanding.
Roche announced the global launch of AXELIOS 1, their next‑generation single-molecule sequencing platform and the first powered by proprietary sequencing by expansion (SBX) technology.
AXELIOS 1 aims to combine accuracy, speed, flexibility, scalability, and cost efficiency to addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will enable researchers to make significant discoveries that enhance our understanding of diseases, with the potential to replace existing technologies in pivotal research areas.
The AXELIOS 1 platform’s flexible sequencing run setup and high-throughput effortlessly handle everything from small-scale studies to massive genomic projects, ensuring laboratories can expand their research capabilities with a single instrument. For researchers, this flexible and open setup grants broader freedom of exploration and new workflows that can truly expand our knowledge of complex diseases.
Axelios 1 is for Research Use Only and not commercially available in the United States. Not for use in diagnostic procedures.
